---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-012769"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:42:04.379665+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# MAIA presents Phase 2 THIO-101 poster at WCLC showing PFS improvement in advanced NSCLC

## Summary
- Poster titled 'Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS' presented at 2025 WCLC on Sept 7, 2025.
- Data from Phase 2 THIO-101 trial evaluating THIO + cemiplimab in advanced NSCLC patients who failed ≥2 prior therapies.
- Specific efficacy numbers (e.g., median PFS, response rates) not disclosed in the filing; poster available on company website Sept 8.
- No safety or additional endpoints described in this filing.

## SEC filing metadata
- accession: 0001493152-25-012769
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225012769/0001493152-25-012769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225012769/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-012769
- JSON: https://secwatch.observer/filing/0001493152-25-012769.json
- Plain text: https://secwatch.observer/filing/0001493152-25-012769.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.